Document:

Exhibit

Exhibit 10.35

IDACORP, Inc. and Idaho Power Company Compensation for
Non-Employee Directors of the Board of Directors
(Effective January 1, 2020)

All directors of IDACORP also serve as directors of Idaho Power.  The fees and other compensation discussed below are for service on both boards.  Employee directors receive no compensation for service on the boards.  

	
					
	Form of Fee
	 
	Amount

	Base Board Annual Retainer
	 
	$
	80,000
	

	 
	 
	 

	Base Committee Annual Retainers
	 
	 

	Audit Committee
	 
	12,000
	

	Compensation Committee
	 
	7,000
	

	Corporate Governance and Nominating Committee
	 
	6,000
	

	Executive Committee
	 
	3,000
	

	 
	 
	 

	Additional Chair Annual Retainers
	 
	 

	Chairperson of the Board of Directors
	 
	100,000
	

	Chair of the Audit Committee
	 
	14,000
	

	Chair of the Compensation Committee
	 
	12,000
	

	Chair of the Corporate Governance and Nominating Committee
	 
	10,000
	

	 
	 
	 

	Annual Stock Awards
	 
	110,000
	

	 
	 
	 

	 
	 
	 

	 

Deferral Arrangements

Directors may defer all or a portion of their annual IDACORP, Idaho Power, IDACORP Financial Services, Inc., and Ida-West Energy retainers and meeting fees and receive a lump-sum payment of all amounts deferred with interest or a series of up to 10 equal annual payments after they separate from service with IDACORP and Idaho Power. Any cash fees that were deferred before 2009 for service as a member of the board of directors were credited with the preceding month’s average Moody’s Long-Term Corporate Bond Yield for utilities, or the Moody’s Rate, plus 3%, until January 1, 2019 when the interest rate changed to the Moody’s Rate. All cash fees that are deferred for service as a member of the board of directors after January 1, 2009 are credited with interest at the Moody’s Rate. Interest is calculated on a pro rata basis each month using a 360-day year and the average Moody’s Rate for the preceding month.

Directors may also defer their annual stock awards, which are then held as deferred stock units with dividend equivalents reinvested in additional deferred stock units. Upon separation from service with IDACORP and Idaho Power, directors will receive either a lump-sum distribution or a series of up to 10 equal annual installments. Upon a change in control the directors’ deferral accounts will be distributed to each participating director in a lump sum. The distributions will be in shares of IDACORP common stock, with each deferred stock unit equal to one share of IDACORP common stock and any fractional shares paid in cash.Exhibit 10.1 

     

      

    
      
        	
                EXECUTION COPY

              

      

      

        Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that the information is (i) not material and (ii) would likely cause
          competitive harm to Compugen Ltd. if publicly disclosed.

      

      

      AMENDMENT NO. 1 TO MASTER CLINICAL TRIAL COLLABORATION AGREEMENT

      

      

      THIS AMENDMENT NO. 1 TO MASTER
          CLINICAL TRIAL COLLABORATION AGREEMENT (this “Amendment”) is effective as of February 14, 2020 (“Amendment Effective Date”)

        by and between Compugen Ltd., an Israeli corporation with a place of business at Azrieli Center, 26 Harokmim Street, Building D, Holon 5885849, Israel (“Compugen”),
        and Bristol-Myers Squibb Company, a Delaware corporation, headquartered at 430 E. 29th Street, 14FL, New York, N.Y. 10016 (“BMS”).

       

      BACKGROUND

       

      A.          BMS and Compugen entered into that certain Master Clinical Trial Collaboration Agreement, dated as of October
          10, 2018 (the “Agreement”).

      

      

      B.          The Parties have mutually agreed to amend the Agreement as follows in accordance with
          Section 13.7 of the Agreement.

       

      NOW, THEREFORE, in consideration of the mutual covenants and undertakings contained herein, and on the terms and subject to the
        conditions set forth herein, the Parties hereby agree as follows:

      

      

      1.          Capitalized terms used and not otherwise defined herein shall have the meaning given to
          such terms in the Agreement.

       

      
        
          	

                	2.	
                   Section 1.34 shall be deleted in its entirety from the Agreement.

                

        

      

      

      

      3.          The definition of “Exclusive Collaboration Period” as set forth in Section 1.48 is hereby amended and restated
          in its entirety as follows:

       

      
        
          
            	“1.48	

                  	
                    
                      “Exclusive Collaboration Period” means the period commencing on the Effective Date and ending on the earliest of:

                    

                  

          

        

        

        

      

      
        
          	

                	(a)	
                  six (6) months after Study Completion of the Triple Study as set forth in Study Plan No. 2; or

                

        

      

       

      
        
          	

                	(b)	
                  the effective date of termination of this Agreement pursuant to Section 12.2, Section 12.3 or Section 12.4.”

                

        

      

      

      

      4.          Study Plan No. 1 previously attached to the Agreement is hereby replaced with the revised
          Study Plan No. 1 attached as Attachment A hereto.

       

      5.          Clause (a) of Exhibit E to the Agreement is hereby amended and restated in its entirety as follows:

       

      

      
        Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.

      

      
        
          

      

      
      
        
          	
                  EXECUTION COPY

                

        

      

       

        

      “Neither Party is obligated to conduct additional studies of the Combined Therapy with the other Party upon completion of a Combined
        Therapy Study, subject to the following provisions of this Exhibit E; provided that the provisions of this Exhibit E are not applicable to any Combined Therapy Study other than the Triple Study. The provisions as set forth in this Exhibit E shall
        only be in effect (and the Parties will only have the rights set forth below in this Exhibit E) with respect to each Subsequent Study for which (x) the proposed protocol synopsis has been submitted by the Proposing Party to the Other Party (as set
        forth below) within the earlier of (i) [*] or (ii) [*]; provided that the proposed Subsequent Study must be commenced [*] within [*] of such protocol synopsis being provided to the Other Party and (y) at the time the proposed protocol synopsis has
        been submitted by the Proposing Party to the Other Party (as set forth below), the Other Party’s Compound is commercialized or in active development; provided that, in the case of BMS, both of the BMS
        Compounds included in the Triple Study must be commercialized or in active development. For clarity, a Subsequent Study may be conducted only for a Combined Therapy for which the Parties agreed to conduct a Combined Therapy Study under this
        Agreement; provided that neither Party has the rights or obligations set forth below in this Exhibit E with respect to any Combined Therapy Study other than the Triple Study. For clarity, if Compugen conducts a study of a therapy using both the
        Compugen Compound and the BMS Compound in addition to the Combined Therapy Study as described in Study Plan No. 1 and BMS does not supply any BMS Compound pursuant to this Agreement for such study, such study shall not be considered a Combined
        Therapy Study pursuant to this Agreement.

      

      

      6.          Clause (d)(iv) of Exhibit E to the Agreement is hereby amended and restated in its
          entirety as follows:

      

      

      “(iv) for the Subsequent Studies where Compugen is the non-Participating Other Party, [*]”

      

      

      7.          Clause (d)(v) of Exhibit E to the Agreement is hereby amended and restated in its
          entirety as follows:

      

      

      “(v) for the Subsequent Studies where BMS is the non-Participating Other Party, [*]

      

      

      8.          Except as amended by this Amendment, the Agreement shall continue in full force and
          effect pursuant to its terms.

      

      

      9.          This Amendment may be executed in two (2) or more counterparts, each of which shall be
          deemed an original, but all of which together shall constitute one (1) and the same instrument. This Amendment may be executed by facsimile or electronic (e.g., .pdf) signatures and such signatures shall be deemed to bind each Party hereto as if
          they were original signature.

      

      

      10.        This Amendment shall be governed and construed in accordance with the internal laws of the State of New York,
          USA, excluding any choice of law rules that may direct the application of the laws of another jurisdiction.

      

      

      [Signature page follows]

       

        

      
        
          Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that the information is
              (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.

        

         

          

        
          2

          
            

        

      

      
        	
                EXECUTION COPY

              

      

       

      IN WITNESS WHEREOF, BMS and Compugen have duly executed this Amendment as of the Amendment Effective Date.

      

      

      	
              COMPUGEN LTD.

            	
              BRISTOL-MYERS SQUIBB COMPANY

            
	 	 
	
              By: _______________________________

            	
              By: _______________________________

                

            
	
              Name: _____________________________

            	
              Name: _____________________________

                

            
	
              Title: ______________________________

            	
              Title: ______________________________

                

            

      

      

      
        Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.

      

      
        3

        
          

      

      
        	
                EXECUTION COPY

              

         

      

      Attachment A

      STUDY PLAN NO. 1

      

      [*]

       

        

      
        Certain confidential information contained in this document, marked by [*], has been omitted because Compugen Ltd. has determined that
            the information is (i) not material and (ii) would likely cause competitive harm to Compugen Ltd. if publicly disclosed.

         

          

      

    

  

   
  4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00304-of-00352.parquet"}]]